



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Closing COVID-19 mortality, vaccination, and evidence gaps for those with severe mental illness

Published Online  
 August 5, 2021  
[https://doi.org/10.1016/S2215-0366\(21\)00291-1](https://doi.org/10.1016/S2215-0366(21)00291-1)  
 See **Articles** page 901

In *The Lancet Psychiatry*, Dana Tzur Bitan and colleagues<sup>1</sup> present the results of the first longitudinal study assessing COVID-19 outcomes before and after vaccination in a cohort of over 25 000 people with schizophrenia and an equally large sample of matched controls in Israel. Particular strengths of this study are the impressive and well-characterised dataset, and the longitudinal design, allowing exploration of dynamic trends over the course of the first year of the COVID-19 pandemic. From a policy perspective, Israel, where all citizens aged 16 and older gained full access to SARS-CoV-2 vaccination as early as January, 2021, represents an interesting case study.

Tzur Bitan and colleagues' analysis suggests that a substantial survival gap persisted between controls and people with schizophrenia throughout the first year of the pandemic. These findings contribute to the growing body of evidence showing severe mental illness, and psychotic disorders in particular, represent a significant and independent risk factor for COVID-19-associated mortality.<sup>2,3</sup> The first reports of increased mortality among people with mental disorders emerged in September, 2020, about halfway through the follow-up period of this study, but these new insights apparently did not translate to specific action or better outcomes for these patients. In fact, the mortality gap was found to be larger in the second half of the follow-up window (HR 2.72 late phase vs 2.15 early phase). Hospital admission rates associated with COVID-19 of people with schizophrenia were also found to be increased in Israel. This finding has been replicated in other studies, although more equivocally, possibly reflecting country differences in health-care organisation and patients' access to care.<sup>2</sup>

Tzur Bitan and colleagues also found a small but significant vaccination gap between controls and people with schizophrenia, confirming earlier preprint findings that patients with schizophrenia are not being vaccinated at the same rate, despite early universal access (in Israel) or priority status (in the UK).<sup>4</sup> In March, 2021, 2 months after its entire adult population became eligible for vaccination, the proportion of fully vaccinated individuals in Israel

was 2.2% lower among people with schizophrenia.<sup>1</sup> Although this finding might seem only a limited and overall acceptable lag, significantly higher prevalences of important comorbid conditions in the cohort with schizophrenia, such as obesity (32.5% vs 22.3%), smoking (51.6% vs 39.3%), diabetes (20.7% vs 13.6%), hyperlipidaemia (47.5% vs 38.5%), and chronic obstructive pulmonary disease (4.6% vs 2.0%), warranted a superior vaccination rate in this group.<sup>5</sup> According to Israel's national vaccination strategy, people with these comorbidities would have been granted priority access to SARS-CoV-2 vaccination before January, 2021. Metabolic comorbidities did predict vaccination status among the patients with schizophrenia included in this study, but this did not lead to an overall higher vaccination proportion among patients with schizophrenia versus controls. It is possible that the predictive effect of the metabolic comorbidities was confounded by these patients' status of more chronic disease and being an inpatient or living in a collective setting, but this hypothesis could not be explored. The immediate implication of this finding is that only granting priority access to patients with severe mental illness in national vaccination strategies does not solve the problem. Even before the first vaccination was administered, policy makers were warned about the decreased likelihood of receipt of other preventive vaccines and the need for targeted interventions to maximise vaccination uptake among these patients.<sup>6</sup> Being eligible for vaccination—with priority or not—is clearly not good enough.<sup>7</sup>

Finally, Tzur Bitan and colleagues' work provides the first preliminary evidence that vaccination offers adequate protection against severe COVID-19 illness in people with schizophrenia, despite concerns about immunological disturbances and suboptimal serological vaccine responses;<sup>8</sup> a reason for hope, which at the same time compels increased efforts. The current findings warn us that even a fully accessible health-care system cannot counteract mortality and vaccination gaps. Coordinated and appropriate interventions are needed to prevent avoidable deaths among patients with severe mental illness. Where

policy makers have failed these patients, it now becomes mental health professionals' duty, in close collaboration with community stakeholders, families and carers, to continue the advocacy efforts, to reach out in any way possible, and to remove any and all barriers that stand in the way of vaccination of people with severe mental illness.<sup>9,10</sup>

Unfortunately, scientific evidence on vaccine hesitancy and the attitudes of people with schizophrenia towards vaccination is a knowledge gap. Although Tzur Bitan and colleagues' study provides a first attempt to characterise determinants of vaccine uptake among patients with schizophrenia, no study to date has stratified patients' COVID-19 outcomes or vaccination rates by their clinical psychiatric status or involvement with psychiatric care. The potential effect of psychiatric care on the pandemic outcomes of these patients thus remains a blind spot. The organisation of care for patients with psychotic disorders is notoriously complex and heterogeneous. Consequently, the pandemic offers a unique opportunity to study the individual (eg, clinical predictors of at-risk groups), mental health-care (eg, treatment setting), and macro-organisational (eg, country health-care system) determinants of COVID-19 outcomes and vaccine uptake among patients with mental disorders. I consider this a priority in the research agenda of mental health-care researchers worldwide. Evidence is the prerequisite for effective action, during and after the COVID-19 pandemic.

I declare no competing interests.

Livia J De Picker

livia.depicker@uantwerp.be

University Psychiatric Hospital Campus Duffel, 2570 Duffel, Belgium;  
Collaborative Antwerp Psychiatric Research Institute, University of Antwerp,  
Antwerp, Belgium

- 1 Tzur Bitan D, Kridin K, Dov Cohen A, Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and post-vaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. *Lancet Psychiatry* 2021; published online Aug 5. [https://doi.org/10.1016/S2215-0366\(21\)00256-X](https://doi.org/10.1016/S2215-0366(21)00256-X).
- 2 Vai B, Mazza MG, Delli Colli C, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. *Lancet Psychiatry* 2021; published online July 15. [https://doi.org/10.1016/S2215-0366\(21\)00232-7](https://doi.org/10.1016/S2215-0366(21)00232-7).
- 3 Nemani K, Li C, Olsson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. *JAMA Psychiatry* 2021; published online April 1. <https://doi.org/10.1001/jamapsychiatry.2020.4442>.
- 4 MacKenna B, Curtis HJ, Morton CE, et al. Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY. *medRxiv* 2021; published online Jan 26. <https://doi.org/10.1101/2021.01.25.21250356> (preprint).
- 5 Tzur Bitan D, Krieger I, Kridin K, et al. COVID-19 prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study. *Schizophr Bull* 2021; published online Feb 19. <https://doi.org/10.1093/schbul/sbab012>.
- 6 Warren N, Kisely S, Siskind D. Maximizing the uptake of a COVID-19 vaccine in people with severe mental illness: a public health priority. *JAMA Psychiatry* 2020; **78**: 589–90.
- 7 The Lancet Psychiatry. A matter of priority: COVID-19 vaccination and mental health. *Lancet Psychiatry* 2021; **8**: 551.
- 8 De Picker LJ, Yolken R, Benedetti F, et al. European COVID-19 exit strategy for people with severe mental disorders: too little, but not yet too late. *Brain Behav Immun* 2021; **94**: 15–17.
- 9 Usher K. Ensuring COVID-19 vaccine uptake by people with severe mental illness: a mental health nursing priority. *Int J Ment Health Nurs* 2021; **30**: 587–89.
- 10 De Picker LJ, Casanova Dias M, Benros ME, et al. Severe mental illness and European COVID-19 vaccination strategies. *Lancet Psychiatry* 2021; **8**: 356–59.

## Three dialectics of disorder: refocusing phenomenology for 21st century psychiatry



An Editorial in *The Lancet Psychiatry*<sup>1</sup> provided a welcome addition to the growing chorus of voices calling for the restoration of phenomenology in psychiatry. Although we agree with these calls, we believe that phenomenology needs to be refocused around the principles of dialectical philosophy if it is to serve the needs of 21st century science-based, but person-centred, mental health care.

Phenomenology is distinctive among disciplines concerned with the subjective lived experience (or lifeworld) of mental distress and disorder, in focusing on the pre-reflective framework within which that experience is set. This pre-reflective framework (simply

in being pre-reflective) is not normally something of which we are aware. Thus, although descriptive psychopathology focuses directly on the contents of lived experience, phenomenology digs below the surface to examine the pre-reflective framework that shapes and gives meaning to that experience. This is why, as the *Lancet Psychiatry* Editorial indicates, contemporary neuroscience has been impoverished by focusing on descriptive psychopathology to the exclusion of the pre-reflective insights of phenomenology.

Dialectical phenomenology adds to other phenomenological approaches in focusing on the relationships between opposite pairs of elements of the pre-reflective

